Patrizia Dell’Orto

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 565 citations

Medicine, Oncology, Surgery +17

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Giuseppe Viale, Meredith M. Regan, Eugenio Maiorano et al. · Journal of Clinical Oncology · 2007 · 456 citations · Full text

Medicine, Endocrinology, Oncology +17

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Giuseppe Viale, Anita Giobbie‐Hurder, Meredith M. Regan et al. · Journal of Clinical Oncology · 2008 · 343 citations · Full text

Medicine, Oncology, Pharmacology +15

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Meredith M. Regan, Brian Leyland‐Jones, Mark Bouzyk et al. · JNCI Journal of the National Cancer Institute · 2012 · 338 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Otto Metzger, Giuseppe Viale, Shayna Stein et al. · Cancer Discovery · 2021 · 240 citations · Full text

Medicine, Cancer Biology, Oncology +15